Press Room

Paperless Lab Academy 2018

Start
Tuesday, March 20, 2018 - 00:00
End
Wednesday, March 21, 2018 - 00:00
Location: Milan, Italy

HOVIONE PRESENTATION

Analytical Lab 4.0: from Digital Twin to Intelligent Systems

Presenters

Andrea Costigliola, Miguel Ramos Lopes

Abstract

Pharma 4.0, the extension of the fourth industrial revolution to the pharmaceutical realm, promises to deliver a productivity leap across key focus areas: drug discovery, development, manufacturing, marketing and quality control. Quality Control (QC) is of paramount importance in the pharmaceutical industry, with companies having to follow strict guidelines enforced by regulatory agencies. Laboratory management is a complex task which involves resources (personnel and equipment) planning and scheduling, analyses prioritization, results evaluation and documentation. The demand for QC work is dependent on other operational areas, fluctuating qualitatively and quantitatively over time. Effective communication mechanisms, visualization and management tools can enhance the overall laboratory service level.

Hovione will leverage the opportunity presented by the design of a new – state-of-the-art – Analytical Laboratory to embrace novel technologies and set the bar for a new paradigm of analytical excellence, turning Analytical Chemistry into a catalyst of operations and a differentiating business factor. In this spirit, we will detail Hovione’s approach by presenting some of our Intelligent Tools (QC Digital Twin, Resource Planner, Tracking Systems, etc.) and the roadmap towards the Analytical Lab 4.0.

 

If you are attending this event and would like to chat with us, schedule a meeting with us.

Schedule a meeting button | Hovione

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026